We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

SIGMA ALDRICH CORP.

Sigma-Aldrich is a life science and high technology company that develops, manufactures, purchases, and distributes v... read more Featured Products: More products

Download Mobile App




Aberrant Gene Expression Predicts Metastatic Endometrial and Lung Cancers

By LabMedica International staff writers
Posted on 10 Feb 2016
The spread of cancer cells from the initial site of occurrence, the primary site, to other secondary tissues is called metastasis, and contributes to poor or limited response of cancer cells to treatments, which results in death. More...
For example, cancer cells initially in the lungs can begin to spread to other organs, including the brain and liver.

Gynecologic cancer typically originates from the female reproductive organs, and includes endometrial and ovarian cancer, among others. Survival rates are typically very poor for these cancer-types, with limited response to existing therapies and a major reason for poor survival rates is late diagnoses, by which time the cancer cells have spread to secondary sites.

Scientists from Georgia State University (Atlanta, GA, USA) and the University of Oklahoma College of Medicine (Oklahoma City, OK, USA) obtained more than a hundred clinical endometrial cancer specimens and matching serum. Using multiplex arrays and a variety of experimental approaches, they analyzed the specimens for gene targets that positively or negatively correlated with metastatic potential of the tumors. Data were translated to reflect the patient's age at diagnosis, disease stage, grade and histology.

Serum specimens were evaluated for levels of c-peptide, interleukin-6 (IL-6,) insulin, leptin, monocyte chemoattractant protein-1 (MCP-1 or CCL2) and tumor necrosis factor alpha (TNFα) using a custom-made multiplex kit subset of the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel (EMD Millipore; Billerica, MA, USA), for levels of adipsin and adiponectin, using the Bio-Plex Pro Human Diabetes Adipsin and Adiponectin Assay (BIO-RAD Laboratories Inc., Hercules, CA, USA; www.bio-rad.com) and for levels of angiopoietin-2, follistatin, G-CSF, HGF, IL-8, leptin, PDGF-BB, PECAM-1 and VEGF, they used the Bio-Rad Bio-Plex Pro diabetes kit.

The scientists found that enhanced neuropilin-1 (NRP-1) expression significantly correlated with increased tumoral expression of vascular endothelial growth factor 2 (VEGFR2) and serum levels of hepatocyte growth factor (HGF) and cell growth-stimulating factor (C-GSF). Tumoral NRP-1 also was positively associated with expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9), a pro-metastatic protein. In the highly metastatic lung cancer cell line (H1792), stable LKB1 depletion caused increased migration in vitro and accentuated NRP-1 and NEDD9 expression in vivo.

Imoh S. Okon, PhD, a professor and lead author of the study said, “In this study, we found that enhanced neuropilin-1 (NRP-1) and NEDD9 levels in endometrial and lung cancer positively correlated with metastasis, while liver kinase B1 (LKB1) inhibited the migration of cancer cells. Our study provides strong translational potential with respect to biomarkers that play critical roles in the development of endometrial/lung tumors.” The study was published on December 20, 2015, in the journal Oncotarget.

Related Links:

Georgia State University 
Oklahoma College of Medicine 
EMD Millipore



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.